Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

917
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
917
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

261
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
261
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.2K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

153
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
153

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Mind the gap: making headway in functional visual loss.

Eye (London, England)·2026
Same author

Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity.

Eye (London, England)·2026
Same author

Infographic: efficacy and safety of intravitreal siRNA therapy for acute NAION (QRK207 trial).

Eye (London, England)·2026
Same author

Infographic: optic nerve decompression surgery for NAION (IONDT Trial).

Eye (London, England)·2026
Same author

Identifying MicroRNA Biomarkers in Idiopathic Intracranial Hypertension: A Pilot Study.

Neurology·2026
Same author

Adult Idiopathic Intracranial Hypertension Without Papilledema: Systematic Review of Literature and Future Perspectives.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2026

Related Experiment Video

Updated: Jan 6, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.5K

A new era for giant cell arteritis.

H S Lyons1, V Quick2, A J Sinclair3,4

  • 1Medical School, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

Eye (London, England)
|October 5, 2019
PubMed
Summary

Giant cell arteritis (GCA), also known as temporal arteritis or Horton's disease, is seeing advances in diagnosis and treatment. New therapies and imaging techniques aim to reduce diagnostic delays and improve patient outcomes.

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.2K
Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices
07:21

Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices

Published on: September 8, 2023

1.0K

Related Experiment Videos

Last Updated: Jan 6, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.5K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.2K
Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices
07:21

Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices

Published on: September 8, 2023

1.0K

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Vascular Medicine

Background:

  • Giant cell arteritis (GCA), or temporal arteritis, presents diagnostic challenges.
  • Delayed diagnosis and glucocorticoid (GC) side effects are significant concerns for patients and clinicians.
  • Current management strategies require updates to address these issues.

Purpose of the Study:

  • To review recent advancements in the investigation and management of GCA.
  • To highlight emerging diagnostic and therapeutic approaches.
  • To discuss future directions in GCA treatment.

Main Methods:

  • Comprehensive literature search of English-language articles.
  • Keywords included: giant cell arteritis, temporal arteritis, Horton's disease, investigation, treatment.
  • Focus on recent advances and emerging trends.

Main Results:

  • Emergence of fast-track diagnostic pathways.
  • Advancements in imaging techniques for GCA detection.
  • Development of novel therapeutic agents beyond traditional glucocorticoids.

Conclusions:

  • The landscape of GCA management is evolving with new diagnostic tools and treatments.
  • These advances promise to mitigate diagnostic delays and reduce GC-related morbidity.
  • Future research will focus on refining intervention strategies for optimal GCA care.